Related references
Note: Only part of the references are listed.Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)
Hideki Ueno et al.
BRITISH JOURNAL OF CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Colon Cancer, Version 2.2021
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
Xiaojie Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
GLUT5 (SLC2A5) enables fructose-mediated proliferation independent of ketohexokinase
Roger J. Liang et al.
CANCER & METABOLISM (2021)
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism
Weiqi Dai et al.
JOURNAL OF HEPATOLOGY (2020)
FOLFOXIRI reintroduction in metastatic colorectal cancer
Rob Glynne-Jones et al.
LANCET ONCOLOGY (2020)
GLUT5 regulation by AKT1/3-miR-125b-5p downregulation induces migratory activity and drug resistance in TLR-modified colorectal cancer cells
Ga-Bin Park et al.
CARCINOGENESIS (2020)
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
Alena Novakova-Jiresova et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns
Marina Salvadores et al.
SCIENCE ADVANCES (2020)
Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities
Carina Neitzel et al.
CANCERS (2020)
Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
Marloes Zoetemelk et al.
MOLECULES (2020)
Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment
Marloes Zoetemelk et al.
MOLECULAR ONCOLOGY (2020)
Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment
Judy R. van Beijnum et al.
CANCERS (2020)
Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure
Maria Giovanna Francipane et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues
Doralicia Casares et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
Marloes Zoetemelk et al.
SCIENTIFIC REPORTS (2019)
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Jesus Garcia-Foncillas et al.
FRONTIERS IN ONCOLOGY (2019)
Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
Andrea Weiss et al.
CANCERS (2019)
Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review
Marcia Vanessa Sales Amaral et al.
ANTICANCER RESEARCH (2019)
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Thomas B. Davis et al.
Oncotarget (2019)
Drug resistance and combating drug resistance in cancer
Xuan Wang et al.
CANCER DRUG RESISTANCE (2019)
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Kaja C. G. Berg et al.
MOLECULAR CANCER (2017)
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations
Satya Narayan et al.
ONCOTARGET (2017)
Maintenance strategy in metastatic colorectal cancer: A systematic review
Ece Esin et al.
CANCER TREATMENT REVIEWS (2016)
Role of Akt signaling in resistance to DNA-targeted therapy
Abolfazl Avan et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2016)
Induction of Epithelial-Mesenchymal Transition and Down-Regulation of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells
Shota Tanaka et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Downregulation of OGDHL expression is associated with promoter hypermethylation in colorectal cancer
M. S. Fedorova et al.
MOLECULAR BIOLOGY (2015)
5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits
Corti Denise et al.
ONCOTARGET (2015)
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
COMBINING TWO-LEVEL AND THREE-LEVEL ORTHOGONAL ARRAYS FOR FACTOR SCREENING AND RESPONSE SURFACE EXPLORATION
Hongquan Xu et al.
STATISTICA SINICA (2014)
In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies
Martina McDermott et al.
FRONTIERS IN ONCOLOGY (2014)
Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status
Amelie Petitprez et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
The SLC2 (GLUT) family of membrane transporters
Mike Mueckler et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Epigenetic and genetic features of 24 colon cancer cell lines
D. Ahmed et al.
ONCOGENESIS (2013)
Quantitative shape analysis of chemoresistant colon cancer cells: Correlation between morphotype and phenotype
A. Pasqualato et al.
EXPERIMENTAL CELL RESEARCH (2012)
Overcoming Resistance to Antiangiogenic Therapies
Sabine Tejpar et al.
ONCOLOGIST (2012)
Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6
Rajesh R. Kaldate et al.
ONCOLOGIST (2012)
Matrix-Bound PAI-1 Supports Cell Blebbing via RhoA/ROCK1 Signaling
Amandine Cartier-Michaud et al.
PLOS ONE (2012)
OGDHL Is a Modifier of AKT-Dependent Signaling and NF-κB Function
Tanusree Sen et al.
PLOS ONE (2012)
Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease
Yiru Xu et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2012)
Oxaliplatin: a review in the era of molecularly targeted therapy
T. Alcindor et al.
Current Oncology (2011)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX
Yingjie Yu et al.
TRANSLATIONAL ONCOLOGY (2009)
Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer
Lee M. Ellis
SEMINARS IN ONCOLOGY (2006)
Mechanisms and strategies to overcome multiple drug resistance in cancer
Tomris Ozben
FEBS LETTERS (2006)
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
D Arango et al.
BRITISH JOURNAL OF CANCER (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
RHJ Mathijssen et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
